Cutaneous T-Cell Lymphoma Treatment: Case Series of Combination Therapy With Intralesional Injections of 5-Fluorouracil and Topical Imiquimod.
Cutaneous T-Cell Lymphoma Treatment: Case Series of Combination Therapy With Intralesional Injections of 5-Fluorouracil and Topical Imiquimod.
- 2023
Available online through MWHC library: 2000 - 2010, Available in print through MWHC library: July 1998 - 2007
Cutaneous T-cell lymphoma (CTCL) is a chronic form of skin cancer. Skin-directed therapies rarely achieve complete clearance of lesions, and recurrences are frequent. In this case series, 9 patients with stage IA to IVA2 CTCL received intralesional (IL) therapy with 5-fluorouracil (5-FU) and imiquimod (IMQ) cream 5% daily to recalcitrant plaques and tumors. All 9 patients attained a complete response (CR) with no recurrences reported and no severe side effects. We find that combination IL 5-FU and IMQ cream 5% daily is a well-tolerated, effective, and durable skin-directed therapy for recalcitrant plaques and tumors in CTCL.
English
0011-4162
10.12788/cutis.0697 [doi] cutis.0697 [pii]
*Lymphoma, T-Cell, Cutaneous
*Skin Neoplasms
Fluorouracil
Humans
Imiquimod/tu [Therapeutic Use]
Injections, Intralesional
Lymphoma, T-Cell, Cutaneous/dt [Drug Therapy]
Skin Neoplasms/pa [Pathology]
MedStar Washington Hospital Center
Dermatology
Medical Dermatology Residency
Journal Article
Available online through MWHC library: 2000 - 2010, Available in print through MWHC library: July 1998 - 2007
Cutaneous T-cell lymphoma (CTCL) is a chronic form of skin cancer. Skin-directed therapies rarely achieve complete clearance of lesions, and recurrences are frequent. In this case series, 9 patients with stage IA to IVA2 CTCL received intralesional (IL) therapy with 5-fluorouracil (5-FU) and imiquimod (IMQ) cream 5% daily to recalcitrant plaques and tumors. All 9 patients attained a complete response (CR) with no recurrences reported and no severe side effects. We find that combination IL 5-FU and IMQ cream 5% daily is a well-tolerated, effective, and durable skin-directed therapy for recalcitrant plaques and tumors in CTCL.
English
0011-4162
10.12788/cutis.0697 [doi] cutis.0697 [pii]
*Lymphoma, T-Cell, Cutaneous
*Skin Neoplasms
Fluorouracil
Humans
Imiquimod/tu [Therapeutic Use]
Injections, Intralesional
Lymphoma, T-Cell, Cutaneous/dt [Drug Therapy]
Skin Neoplasms/pa [Pathology]
MedStar Washington Hospital Center
Dermatology
Medical Dermatology Residency
Journal Article